Barton F Haynes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3758753/publications.pdf

Version: 2024-02-01

256 papers	28,963 citations	7568 77 h-index	6471 157 g-index
277 all docs	277 docs citations	277 times ranked	20259 citing authors

#	Article	IF	Citations
1	Changes in thymic function with age and during the treatment of HIV infection. Nature, 1998, 396, 690-695.	27.8	1,778
2	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7552-7557.	7.1	1,708
3	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine, 2012, 366, 1275-1286.	27.0	1,699
4	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013, 496, 469-476.	27.8	961
5	Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies. Science, 2005, 308, 1906-1908.	12.6	704
6	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature, 2014, 514, 455-461.	27.8	702
7	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature, 2017, 543, 248-251.	27.8	699
8	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1273-1289.	8.5	684
9	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. Journal of Virology, 2008, 82, 12449-12463.	3.4	548
10	<scp>HIV</scp>â€•1 neutralizing antibodies: understanding nature's pathways. Immunological Reviews, 2013, 254, 225-244.	6.0	442
11	B-cellâ€“lineage immunogen design in vaccine development with HIV-1 as a case study. Nature Biotechnology, 2012, 30, 423-433.	17.5	432
12	The Role of the Thymus in Immune Reconstitution in Aging, Bone Marrow Transplantation, and HIV-1 Infection. Annual Review of Immunology, 2000, 18, 529-560.	21.8	430
13	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. Journal of Virology, 2011, 85, 9998-10009.	3.4	393
14	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity, 2013, 38, 176-186.	14.3	374
15	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. Journal of Experimental Medicine, 2018, 215, 1571-1588.	8.5	366
16	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. Immunity, 2013, 39, 245-258.	14.3	332
17	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host and Microbe, 2021, 29, 529-539.e3.	11.0	324
18	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host and Microbe, 2021, 29, 23-31.e4.	11.0	308

#	Article	IF	Citations
19	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292.	28.9	305
20	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell, 2016, 165, 449-463.	28.9	305
21	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity, 2020, 53, 724-732.e7.	14.3	267
22	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell, 2014, 158, 481-491.	28.9	266
23	D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. Cell Reports, 2021, 34, 108630.	6.4	263
24	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i>. Journal of Virology, 2014, 88, 12669-12682.	3.4	248
25	Human Responses to Influenza Vaccination Show Seroconversion Signatures and Convergent Antibody Rearrangements. Cell Host and Microbe, 2014, 16, 105-114.	11.0	246
26	High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. Journal of Virological Methods, 2009, 158, 171-179.	2.1	235
27	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	28.9	228
28	Staged induction of HIV-1 glycanâ€“dependent broadly neutralizing antibodies. Science Translational Medicine, 2017, 9, .	12.4	212
29	Human T Lymphocyte Antigens as Defined by Monoclonal Antibodies. Immunological Reviews, 1981, 57, 127-161.	6.0	208
30	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. Journal of Virology, 2016, 90, 76-91.	3.4	205
31	Prospects for a safe COVID-19 vaccine. Science Translational Medicine, 2020, 12, .	12.4	204
32	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature, 2021, 594, 553-559.	27.8	199
33	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. Journal of Experimental Medicine, 2011, 208, 2237-2249.	8.5	198
34	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell, 2016, 166, 1471-1484.e18.	28.9	198
35	Latency reversal and viral clearance to cure HIV-1. Science, 2016, 353, aaf6517.	12.6	194
36	Diversion of HIV-1 vaccineâ€“induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015, 349, aab1253.	12.6	191

#	Article	IF	Citations
37	Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. Arthritis and Rheumatism, 1989, 32, 22-30.	6.7	186
38	Immune correlates of vaccine protection against HIV-1 acquisition. Science Translational Medicine, 2015, 7, 310rv7.	12.4	179
39	Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 181-186.	7.1	172
40	Envelope residue 375 substitutions in simianâ€"human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3413-22.	7.1	170
41	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology, 2014, 88, 7715-7726.	3.4	169
42	Measurement of an adhesion molecule as an indicator of inflammatory disease activity: Upâ€regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis and Rheumatism, 1991, 34, 1434-1443.	6.7	168
43	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nature Structural and Molecular Biology, 2016, 23, 81-90.	8.2	162
44	Antibodyâ€virus coâ€evolution in <scp>HIV</scp> infection: paths for <scp>HIV</scp> vaccine development. Immunological Reviews, 2017, 275, 145-160.	6.0	160
45	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Reports, 2017, 19, 719-732.	6.4	160
46	Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design. Journal of Virology, 2012, 86, 4688-4692.	3.4	159
47	Polyreactivity and Autoreactivity among HIV-1 Antibodies. Journal of Virology, 2015, 89, 784-798.	3.4	154
48	Viral Receptor-Binding Site Antibodies with Diverse Germline Origins. Cell, 2015, 161, 1026-1034.	28.9	151
49	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens, 2015, 11, e1005042.	4.7	145
50	Multiple roles for HIV broadly neutralizing antibodies. Science Translational Medicine, 2019, 11, .	12.4	144
51	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science, 2021, 373, 991-998.	12.6	144
52	HIV-Host Interactions: Implications for Vaccine Design. Cell Host and Microbe, 2016, 19, 292-303.	11.0	143
53	Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Human Antibodies, 2006, 14, 59-67.	1.5	142
54	Ontogeny of the human thymus during fetal development. Journal of Clinical Immunology, 1987, 7, 81-97.	3.8	141

#	Article	IF	Citations
55	Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion. Journal of Infectious Diseases, 2015, 211, 947-955.	4.0	140
56	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. Cell Host and Microbe, 2014, 16, 304-313.	11.0	137
57	Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E590-E599.	7.1	137
58	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nature Communications, 2017, 8, 15711.	12.8	137
59	Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. PLoS ONE, 2011, 6, e23532.	2.5	137
60	The Human Thymus During Aging. Immunologic Research, 2000, 22, 253-262.	2.9	133
61	Glycosylation Site-Specific Analysis of HIV Envelope Proteins (JR-FL and CON-S) Reveals Major Differences in Glycosylation Site Occupancy, Glycoform Profiles, and Antigenic EpitopesÊ¼ Accessibility. Journal of Proteome Research, 2008, 7, 1660-1674.	3.7	133
62	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. Nature Medicine, 2018, 24, 1590-1598.	30.7	129
63	Structural diversity of the SARS-CoV-2 Omicron spike. Molecular Cell, 2022, 82, 2050-2068.e6.	9.7	125
64	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host and Microbe, 2019, 25, 59-72.e8.	11.0	124
65	Immune perturbations in HIV-1â€“infected individuals who make broadly neutralizing antibodies. Science Immunology, 2016, 1, aag0851.	11.9	120
66	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Science Immunology, 2017, 2, .	11.9	119
67	CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2687-94.	7.1	118
68	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science, 2019, 366, .	12.6	118
69	Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Human Antibodies, 2005, 14, 59-67.	1.5	109
70	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. Cell Host and Microbe, 2014, 16, 215-226.	11.0	105
71	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. Frontiers in Immunology, 2014, 5, 170.	4.8	104
72	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nature Medicine, 2016, 22, 1465-1469.	30.7	104

#	Article	IF	Citations
73	Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Cell Host and Microbe, 2018, 23, 759-765.e6.	11.0	98
74	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Reports, 2017, 21, 3681-3690.	6.4	97
75	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine, 2022, 14, eabj7125.	12.4	93
76	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. Cell, 2020, 181, 1458-1463.	28.9	92
77	The quest for an antibodyâ€based <scp>HIV</scp> vaccine. Immunological Reviews, 2017, 275, 5-10.	6.0	91
78	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Cell Reports, 2018, 25, 893-908.e7.	6.4	91
79	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. Annual Review of Medicine, 2022, 73, 1-16.	12.2	91
80	Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Review of Vaccines, 2006, 5, 347-363.	4.4	90
81	Developing an HIV vaccine. Science, 2017, 355, 1129-1130.	12.6	89
82	Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Review of Vaccines, 2006, 5, 579-595.	4.4	87
83	Glycosylation Site-Specific Analysis of Clade C HIV-1 Envelope Proteins. Journal of Proteome Research, 2009, 8, 4231-4242.	3.7	87
84	Initiation of immune toleranceâ€“controlled HIV gp41 neutralizing B cell lineages. Science Translational Medicine, 2016, 8, 336ra62.	12.4	86
85	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nature Communications, 2018, 9, 1928.	12.8	83
86	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine, 2017, 9, .	12.4	81
87	Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. Cell Reports, 2018, 25, 107-117.e3.	6.4	79
88	Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. Molecular Therapy - Nucleic Acids, 2019, 15, 36-47.	5.1	79
89	Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies. PLoS Computational Biology, 2010, 6, e1000955.	3.2	78
90	RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. Cell, 2018, 175, 387-399.e17.	28.9	78

#	Article	IF	Citations
91	Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10. Journal of Immunology, 2013, 191, 1260-1275.	0.8	77
92	New approaches to HIV vaccine development. Current Opinion in Immunology, 2015, 35, 39-47.	5.5	77
93	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity, 2019, 50, 677-691.e13.	14.3	77
94	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	12.8	76
95	Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18214-18219.	7.1	73
96	Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10275-10280.	7.1	73
97	Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. Journal of Virology, 2017, 91, .	3.4	73
98	Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein. Journal of the American Society for Mass Spectrometry, 2008, 19, 1209-1220.	2.8	69
99	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Reports, 2017, 18, 2175-2188.	6.4	69
100	Critical issues in mucosal immunity for HIV-1 vaccine development. Journal of Allergy and Clinical Immunology, 2008, 122, 3-9.	2.9	68
101	Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. Nature Immunology, 2020, 21, 199-209.	14.5	68
102	Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. Cell Reports, 2015, 13, 2842-2850.	6.4	67
103	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	11.0	66
104	Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple De Novo Genome Assemblies. Frontiers in Immunology, 2017, 8, 1407.	4.8	66
105	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. Immunity, 2014, 41, 909-918.	14.3	65
106	Host controls of <scp>HIV</scp> broadly neutralizing antibody development. Immunological Reviews, 2017, 275, 79-88.	6.0	65
107	Cold sensitivity of the SARS-CoV-2 spike ectodomain. Nature Structural and Molecular Biology, 2021, 28, 128-131.	8.2	65
108	The human thymus. Immunologic Research, 1998, 18, 175-192.	2.9	64

#	Article	IF	Citations
109	Host Controls of HIV Neutralizing Antibodies. Science, 2014, 344, 588-589.	12.6	63
110	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. Cell Reports, 2021, 35, 109179.	6.4	63
111	The human thymus. Immunologic Research, 1998, 18, 61-78.	2.9	62
112	Progress in HIV-1 vaccine development. Journal of Allergy and Clinical Immunology, 2014, 134, 3-10.	2.9	62
113	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. Journal of Virology, 2016, 90, 5899-5914.	3.4	62
114	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity, 2018, 49, 1162-1174.e8.	14.3	61
115	Chemical Synthesis of Highly Congested gp120 V1V2 <i>N</i>-Glycopeptide Antigens for Potential HIV-1-Directed Vaccines. Journal of the American Chemical Society, 2013, 135, 13113-13120.	13.7	60
116	Synovial microenvironment-t cell interactions. Arthritis and Rheumatism, 1988, 31, 947-955.	6.7	57
117	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell, 2021, 184, 2955-2972.e25.	28.9	57
118	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008026.	4.7	56
119	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine, 2021, 2, 100313.	6.5	56
120	CD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies. Journal of Virology, 2014, 88, 6542-6555.	3.4	55
121	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. Journal of Virology, 2011, 85, 7719-7729.	3.4	54
122	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. Journal of Virology, 2017, 91, .	3.4	52
123	Human Erythrocyte Antigens. Vox Sanguinis, 1987, 52, 236-243.	1.5	50
124	A New Vaccine to Battle Covid-19. New England Journal of Medicine, 2021, 384, 470-471.	27.0	50
125	Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. JCI Insight, 2019, 4, .	5.0	50
126	BCR and Endosomal TLR Signals Synergize to Increase AID Expression and Establish Central B Cell Tolerance. Cell Reports, 2017, 18, 1627-1635.	6.4	49

#	Article	IF	Citations
127	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science, 2021, 371, .	12.6	49
128	Contribution of proteasome-catalyzed peptide<i>cis</i>-splicing to viral targeting by CD8⁺T cells in HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24748-24759.	7.1	48
129	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine, 2016, 14, 97-111.	6.1	47
130	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology, 2018, 92, .	3.4	46
131	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nature Communications, 2018, 9, 2363.	12.8	46
132	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. Npj Vaccines, 2021, 6, 50.	6.0	46
133	Thymopoiesis in HIV-Infected Adults after Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2001, 17, 1635-1643.	1.1	45
134	High throughput functional analysis of HIV-1 env genes without cloning. Journal of Virological Methods, 2007, 143, 104-111.	2.1	45
135	Progress in HIV-1 vaccine development. Current Opinion in HIV and AIDS, 2013, 8, 1.	3.8	45
136	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Reports, 2016, 14, 43-54.	6.4	45
137	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology, 2018, 92, .	3.4	45
138	HIV mRNA Vaccinesâ€"Progress and Future Paths. Vaccines, 2021, 9, 134.	4.4	45
139	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. PLoS ONE, 2016, 11, e0157409.	2.5	44
140	A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. Cell Reports, 2016, 15, 1505-1513.	6.4	43
141	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. Cell Reports, 2020, 31, 107624.	6.4	43
142	Cytokines and adhesion molecules in the pathogenesis of vasculitis. Current Rheumatology Reports, 2000, 2, 402-410.	4.7	42
143	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8614-8619.	7.1	42
144	Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. Nature Communications, 2020, 11, 520.	12.8	42

#	Article	IF	Citations
145	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Molecular Therapy, 2016, 24, 2021-2032.	8.2	41
146	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. PLoS ONE, 2019, 14, e0215163.	2.5	41
147	Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Translational Research, 2022, 242, 38-55.	5.0	41
148	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Journal of Virology, 2015, 89, 6462-6480.	3.4	40
149	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. Journal of Virology, 2016, 90, 5031-5046.	3.4	38
150	Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology, 2006, 345, 44-55.	2.4	37
151	B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends in Molecular Medicine, 2011, 17, 108-116.	6.7	37
152	IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria. PLoS ONE, 2014, 9, e90725.	2.5	37
153	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathogens, 2018, 14, e1007431.	4.7	36
154	Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. Journal of Virology, 2015, 89, 7813-7828.	3.4	35
155	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nature Communications, 2019, 10, 2898.	12.8	35
156	The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. Cell Reports, 2019, 27, 2426-2441.e6.	6.4	35
157	Leukemia-associated arthritis: identification of leukemic cells in synovial fluid using monoclonal and polyclonal antibodies. Arthritis and Rheumatism, 1984, 27, 1306-1308.	6.7	34
158	Conformational Preferences of a Chimeric Peptide HIV-1 Immunogen from the C4â^'V3 Domains of gp120 Envelope Protein of HIV-1 CAN0A Based on Solution NMR:â€‰ Comparison to a Related Immunogenic Peptide from HIV-1 RF. Biochemistry, 1996, 35, 5158-5165.	2.5	34
159	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 2016, 12, 196-207.	6.1	34
160	Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. Mucosal Immunology, 2017, 10, 228-237.	6.0	34
161	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. Nature Communications, 2019, 10, 654.	12.8	34
162	Increase in TCR?? T lymphocytes in synovia from rheumatoid arthritis patients with active synovitis. Journal of Clinical Immunology, 1992, 12, 130-138.	3.8	33

#	Article	IF	Citations
163	Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. PLoS Biology, 2019, 17, e3000328.	5.6	33
164	Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. PLoS ONE, 2016, 11, e0157391.	2.5	33
165	Self-tolerance curtails the B cell repertoire to microbial epitopes. JCI Insight, 2019, 4, .	5.0	32
166	HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. Nature Communications, 2018, 9, 1111.	12.8	30
167	Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. Journal of Virology, 2017, 91, .	3.4	29
168	Is developing an HIV-1 vaccine possible?. Current Opinion in HIV and AIDS, 2010, 5, 362-367.	3.8	28
169	Designing synthetic vaccines for HIV. Expert Review of Vaccines, 2015, 14, 815-831.	4.4	28
170	Immune checkpoint modulation enhances HIV-1 antibody induction. Nature Communications, 2020, 11, 948.	12.8	27
171	Normalization of the peripheral blood T cell receptor V beta repertoire after cultured postnatal human thymic transplantation in DiGeorge syndrome. Journal of Clinical Immunology, 1997, 17, 167-175.	3.8	26
172	HIV-1 Hides an Achilles' Heel in Virion Lipids. Immunity, 2008, 28, 10-12.	14.3	26
173	Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology, 2014, 11, 78.	2.0	26
174	HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development. PLoS Pathogens, 2014, 10, e1004073.	4.7	26
175	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. Viruses, 2015, 7, 5443-5475.	3.3	26
176	Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. AIDS Research and Human Retroviruses, 2017, 33, 428-431.	1.1	26
177	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Communications Biology, 2018, 1, 134.	4.4	26
178	Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. Cell Reports Medicine, 2021, 2, 100207.	6.5	26
179	Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies. Vaccines, 2014, 2, 1-14.	4.4	25
180	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology, 2015, 475, 37-45.	2.4	25

#	Article	IF	Citations
181	Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. MBio, 2020, 11, .	4.1	25
182	Improving Mycobacterium bovis Bacillus Calmette-GuÃ¨rin as a Vaccine Delivery Vector for Viral Antigens by Incorporation of Glycolipid Activators of NKT Cells. PLoS ONE, 2014, 9, e108383.	2.5	24
183	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. Journal of Virology, 2018, 92, .	3.4	24
184	Analysis of FcÎ³ receptors on human peripheral blood leukocytes by flow microfluorometry. I. Receptor distributions on monocytes, TÎ³ cells and cells labeled with the 3A1 anti-T cell monoclonal antibody. European Journal of Immunology, 1982, 12, 474-479.	2.9	23
185	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. Journal of Virology, 2016, 90, 4951-4965.	3.4	23
186	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. Journal of Virology, 2017, 91, .	3.4	23
187	Vaccine Innovations â€" Past and Future. New England Journal of Medicine, 2021, 384, 393-396.	27.0	23
188	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Reports, 2022, 38, 110514.	6.4	23
189	Glycoengineering HIV-1 Env creates â€˜superchargedâ€™ and â€˜hybridâ€™ glycans to increase neutralizing antibody potency, breadth and saturation. PLoS Pathogens, 2018, 14, e1007024.	4.7	22
190	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. Journal of Clinical Investigation, 2020, 130, 5157-5170.	8.2	22
191	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. Cell Reports, 2020, 30, 1553-1569.e6.	6.4	21
192	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure. Journal of Virology, 2021, 95, .	3.4	21
193	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. Journal of Virology, 2017, 91, .	3.4	20
194	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. Nature Immunology, 2021, 22, 1294-1305.	14.5	20
195	Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. Open Forum Infectious Diseases, 2014, 1, ofu056.	0.9	19
196	The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved Human Peripheral Blood Mononuclear Cells. Journal of Immunological Methods, 2014, 409, 21-30.	1.4	19
197	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Journal of Virology, 2017, 91, .	3.4	19
198	Strategies for induction of HIVâ€1 envelopeâ€reactive broadly neutralizing antibodies. Journal of the International AIDS Society, 2021, 24, e25831.	3.0	19

#	Article	IF	Citations
199	Rheumatoid arthritis and sterile corneal ulceration. Arthritis and Rheumatism, 1984, 27, 606-614.	6.7	18
200	In vivo models of human lymphopoiesis and autoimmunity in severe combined immune deficient mice. Journal of Clinical Immunology, 1992, 12, 311-324.	3.8	18
201	Distribution of CD44 variant isoforms in human skin: differential expression in components of benign and malignant epithelia. Journal of Cutaneous Pathology, 1995, 22, 536-545.	1.3	18
202	HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?. Nature Structural and Molecular Biology, 2010, 17, 543-545.	8.2	18
203	HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. Immunogenetics, 2016, 68, 145-155.	2.4	18
204	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. AIDS Research and Human Retroviruses, 2017, 33, 859-868.	1.1	18
205	HIV vaccine delayed boosting increases Env variable region 2â€"specific antibody effector functions. JCI Insight, 2020, 5, .	5.0	18
206	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. Journal of Virology, 2014, 88, 9406-9417.	3.4	16
207	Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors. Vaccine Journal, 2015, 22, 726-741.	3.1	16
208	Broadly Neutralizing Antibodies and the Development of Vaccines. JAMA - Journal of the American Medical Association, 2015, 313, 2419.	7.4	15
209	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. Communications Biology, 2022, 5, 271.	4.4	14
210	Recombinant Mycobacterium bovis Bacillus Calmette-GuÃ©rin Vectors Prime for Strong Cellular Responses to Simian Immunodeficiency Virus Gag in Rhesus Macaques. Vaccine Journal, 2014, 21, 1385-1395.	3.1	13
211	Gene Deletions in Mycobacterium bovis BCG Stimulate Increased CD8⁺T Cell Responses. Infection and Immunity, 2014, 82, 5317-5326.	2.2	13
212	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine, 2015, 2, 713-722.	6.1	13
213	Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection. Frontiers in Microbiology, 2018, 9, 1326.	3.5	13
214	Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination. Current Opinion in Virology, 2021, 51, 172-178.	5.4	13
215	Preexisting compensatory amino acids compromise fitness costs of a HIV-1ÂT cell escape mutation. Retrovirology, 2014, 11, 101.	2.0	12
216	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS ONE, 2017, 12, e0176428.	2.5	12

#	Article	IF	Citations
217	Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5. Journal of Immunology, 2019, 203, 3268-3281.	0.8	12
218	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. Npj Vaccines, 2020, 5, 36.	6.0	12
219	Redemption of autoreactive B cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9022-9023.	7.1	11
220	Eliminating antibody polyreactivity through addition of <i>N</i>â€linked glycosylation. Protein Science, 2015, 24, 1019-1030.	7.6	11
221	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. Npj Vaccines, 2020, 5, 107.	6.0	11
222	Computational analysis of antibody dynamics identifies recent HIV-1 infection. JCI Insight, 2017, 2, .	5.0	11
223	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of Virology, 2018, 92, .	3.4	10
224	What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029397.	5.5	10
225	Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7929-7940.	7.1	10
226	Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2016, 35, 217-226.	1.6	9
227	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. Cell Reports, 2021, 36, 109561.	6.4	9
228	Lessons from babies: inducing HIV-1 broadly neutralizing antibodies. Nature Medicine, 2014, 20, 583-585.	30.7	7
229	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. Journal of Immunology, 2017, 198, 1047-1055.	0.8	7
230	HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. Scientific Reports, 2019, 9, 10165.	3.3	7
231	SARS-CoV-2 and HIV-1 â€" a tale of two vaccines. Nature Reviews Immunology, 2021, 21, 543-544.	22.7	7
232	Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. Journal of Virology, 2021, , JVI0164321.	3.4	7
233	The mouseCD7 gene: Identification of a new element common to the humanCD7 and mouseThy-1 promoters. Immunogenetics, 1996, 44, 108-114.	2.4	6
234	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. Journal of Immunology, 2016, 197, 4663-4673.	0.8	6

#	Article	IF	Citations
235	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. MBio, 2020, 11, .	4.1	6
236	Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin. Frontiers in Immunology, 2020, 11, 156.	4.8	6
237	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth. Scientific Reports, 2021, 11, 14494.	3.3	6
238	Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. Journal of Clinical Investigation, 2021, 131, .	8.2	6
239	Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. PLoS Pathogens, 2019, 15, e1008165.	4.7	5
240	Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. Journal of Virology, 2020, 94, .	3.4	5
241	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. Cell Reports, 2021, 37, 109922.	6.4	5
242	Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. Vaccine, 2014, 32, 3995-4000.	3.8	4
243	Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1. Molecular Therapy - Methods and Clinical Development, 2019, 14, 148-160.	4.1	4
244	Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. Journal of Virological Methods, 2017, 249, 85-93.	2.1	2
245	Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. MSphere, 2020, 5, .	2.9	2
246	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. PLoS Pathogens, 2021, 17, e1009624.	4.7	2
247	The mouse CD7 gene: identification of a new element common to the human CD7 and mouse Thy-1 promoters. Immunogenetics, 1996, 44, 108-114.	2.4	1
248	Can the thymus win the battle against drug-resistant HIV?. Nature Medicine, 2001, 7, 661-662.	30.7	1
249	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAXÂ® B/E in RV144 Vaccinees. AIDS Research and Human Retroviruses, 2014, 30, A36-A36.	1.1	1
250	ÂÂÂÂRapid Selection of HIV Envelopes that Bind to Neutralizing Antibody B Cell Lineage Members with Functional Improbable Mutations. SSRN Electronic Journal, 0, , .	0.4	1
251	<i>Response</i> : HIV Viral Load Assay. Science, 1996, 271, 1043-1043.	12.6	1
252	HIV Vaccine Development at Duke University Medical Center. Immunologic Research, 2000, 22, 263-270.	2.9	0

#	Article	IF	Citations
253	How Does HIV Env Structure Informs Vaccine Design?. Microscopy and Microanalysis, 2020, 26, 574-575.	0.4	0
254	Response : HIV Viral Load Assay. Science, 1996, 271, 1043-1043.	12.6	0
255	<i>Response</i> : HIV Quasispecies and Resampling. Science, 1996, 273, 416-416.	12.6	0
256	-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures. ImmunoHorizons, 2020, 4, 713-728.	1.8	0